BDTX-1535 is a small molecule commercialized by Black Diamond Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BDTX-1535’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for BDTX-1535 is expected to reach an annual total of $109 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

BDTX-1535 Overview

BDTX-1535 is under development for the treatment of recurrent glioblastoma, non-small cell lung cancer (NSCLC), high grade glioma and newly diagnosed glioblastoma. The drug candidate is administered orally and acts by targeting the family of epidermal growth factor receptor (EGFR) variants implicated in glioblastoma, as well as Exon 18 mutations and the C797S mutations in NSCLC. It is being developed based on MAP (mutation, allostery and pharmacology) platform.

Black Diamond Therapeutics Overview

Black Diamond Therapeutics (Black Diamond) is a precision oncology medicine company. It discovers small molecules and tumor-agnostic therapies for the treatment of cancer. The company’s pipeline product candidates include BDTX- 4933 is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations; and BDTX-1535, a brain-penetrant small-molecule inhibitor for the treatment of glioblastoma, affecting the brain or spine. It is also developing its Mutation-Allostery-Pharmacology (MAP) technology platform, to identify oncogenic mutations that promote cancer. Black Diamond is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$86.5 million in FY2023, compared to an operating loss of US$92.8 million in FY2022. The net loss of the company was US$82.4 million in FY2023, compared to a net loss of US$91.2 million in FY2022.

For a complete picture of BDTX-1535’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.